

FEE TRANSMITTAL

Patent fees are subject to annual revision.

APR 18 2002

Complete if Known

Application Number 10/031,691
Filing Date January 22, 2002
First Named Inventor Uebele, et al.
Examiner Name
Group Art Unit
Attorney Docket Number 20499P

TOTAL AMOUNT OF PAYMENT

\$130

METHOD OF PAYMENT (Check one)

1. ☒ The Commissioner is hereby authorized to charge indicated fees and credit any overpayments to:

Deposit Account Number

13-2755

Deposit Account Name

Merck & Co., Inc.

- ☒ Charge Any Additional Fee Required Under 37 CFR 1.16 and 1.17

2. ☐ Payment Enclosed:

☐ Check ☐ Money Order ☐ Other

FEE CALCULATION

1. BASIC FILING FEE

Large Fee Code	Entity Fee (\$)	Fee Description	Fee Paid
101	740	Utility filing fee	
106	330	Design filing fee	
108	740	Reissue filing fee	
114	160	Provisional filing fee	
SUBTOTAL(1)			\$0

2. EXTRA CLAIM FEES

	Extra	Fee from below	Fee Paid
Total Claims	20 ** = 0	x \$18 =	0
Independent Claims	3 ** = 0	x \$84 =	0
Multiple Dependent Claims		\$280 =	

**or number previously paid, if greater; For Reissues, see below

Large Fee Code	Entity Fee (\$)	Fee Description
103	18	Claims in excess of 20
102	84	Independent claims in excess of 3
104	280	Multiple dependent claim, if not paid
109	84	**Reissue independent claims over original patent
110	18	**Reissue claims in excess of 20 and over original patent
SUBTOTAL(2)		\$0

3. ADDITIONAL FEES

Large Fee Code	Entity Fee (\$)	Fee Description	Fee Paid
105	130	Surcharge - late filing fee or oath	130
147	2,520	For filing a request for reexamination	
115	110	Extension for reply within first month	
116	400	Extension for reply within second month	
117	920	Extension for reply within third month	
118	1,440	Extension for reply within fourth month	
128	1,960	Extension for reply within fifth month	
119	320	Notice of Appeal	
120	320	Filing a brief in support of an appeal	
121	280	Request for oral hearing	
140	110	Petition to revive - unavoidable	
141	1,280	Petition to revive - unintentional	
142	1,280	Utility issue fee (or reissue)	
143	460	Design issue fee	
122	130	Petitions to the Commissioner	
123	50	Petitions related to provisional applications	
126	180	Submission of Information Disclosure Statement	
581	40	Recording each patent assignment per property (times number of properties)	
146	740	Filing a submission after final rejection (37 CFR 1.129(a))	
149	740	For each additional invention to be examined (37 CFR 1.129(b))	
179	740	Request for Continued Examination (RCE)	
Other fee (specify)			
Other fee (specify)			
SUBTOTAL(3)			\$130

SUBMITTED BY

Typed or Printed Name

Joseph A. Coppola

Signature

Joseph A. Coppola

Date


04/12/2002

Complete (if applicable)

Reg. Number 38,413

Deposit Account User ID

Application Number: 10/031,691
Filing Date: 01/22/2002
First Named Inventor: Uebele, et al.
Group Art Unit: _____
Examiner Name: _____
Attorney Docket Number: 20499P



FIRST CLASS MAIL CERTIFICATE

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO: ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231, ON THE DATE APPEARING BELOW.

MERCK & CO., INC.

MAILED BY

Kanaye York

DATE

April 12, 2002



UNITED STATES PATENT AND TRADEMARK OFFICE

APR 18 2002

Commissioner for Patents, Box PC-1
United States Patent and Trademark Office
Washington, D.C. 20231
www.uspto.gov

U.S. APPLICATION NUMBER NO	FIRST NAMED APPLICANT	ATTY. DOCKET NO
10/031,691	Victor Uebele	20499P

Merck & Company
Patent Department, RY60-30
P O Box 2000
126 East Lincoln Avenue
Rahway, NJ 07065-0970

*Oath &
Declaration
& Sequence Requirements
Due
6/3/02*

INTERNATIONAL APPLICATION NO
PCT/US00/19585
I.A. FILING DATE
PRIORITY DATE

07/18/2000

CONFIRMATION NO. 8269

371 FORMALITIES LETTER



OC000000007774557

Date Mailed: 04/03/2002

NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as an Elected Office (37 CFR 1.495):

- U.S. Basic National Fees
- Biochemical Sequence Listing
- Copy of IPE Report
- Copy of references cited in ISR
- Copy of the International Application
- Copy of the International Search Report

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

- Oath or declaration of the inventors, in compliance with 37 CFR 1.497(a) and (b), identifying the application by the International application number and international filing date.

ALL OF THE ITEMS SET FORTH ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTH FROM THE DATE OF THIS NOTICE OR BY 22 or 32 MONTHS (where 37 CFR 1.495 applies) FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

The following items **MUST** be furnished within the period set forth below:

- The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):

- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
- APPLICANT MUST PROVIDE:
 - An initial or substitute computer readable form (CRF) of the "Sequence Listing."
 - A statement that the contents of the paper or compact disc and the computer readable form are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).

• For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

LAMONT M HUNTER

Telephone: (703) 305-3686

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/031,691	PCT/US00/19585	20499P

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	Uebele, et al.
Serial No.:	10/031,691 - Case No.: 20499P
Filed:	January 22, 2002
For:	NOVEL HUMAN CALCIUM SENSITIVE POTASSIUM CHANNEL

Art Unit:

Examiner:

Assistant Commissioner for Patents
Washington, D.C. 20231

SUBMISSION OF SEQUENCE STATEMENT

Sir:

Please insert the enclosed Sequence Listing in paper and computer readable form into the above-identified application. The Sequence Listing does not contain new matter. The contents of the paper and computer readable forms of the Sequence Listing are the same.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on the date appearing below.

By Karey York Date 4/12/02
MERCK & CO., INC.

Respectfully submitted,

By Joseph A. Coppola
Joseph A. Coppola
Reg. No. 38,413
Attorney for Applicant

MERCK & CO., INC.
P.O. Box 2000
Rahway, New Jersey 07065-0907
(732) 594-6734

Date: APRIL 12, 2002